<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11863030</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.626</article-id><article-id pub-id-type="other">EPP0491</article-id><article-id pub-id-type="pii">S0924933824006266</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Weight changes in esketamine nasal spray and quetiapine extended-release treated patients with treatment resistant depression: Results from ESCAPE-TRD study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Reif</surname><given-names>A.</given-names></name><xref rid="aff1448" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff1449" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cor0487" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Fagiolini</surname><given-names>A.</given-names></name><xref rid="aff1450" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Buntinx</surname><given-names>E.</given-names></name><xref rid="aff1451" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ruggeri</surname><given-names>H.</given-names></name><xref rid="aff1452" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Godinov</surname><given-names>Y.</given-names></name><xref rid="aff1453" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Buyze</surname><given-names>J.</given-names></name><xref rid="aff1454" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mulhern-Haughey</surname><given-names>S.</given-names></name><xref rid="aff1455" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bitter</surname><given-names>I.</given-names></name><xref rid="aff1456" ref-type="aff">
<sup>9</sup>
</xref></contrib></contrib-group><aff id="aff1448"><sup>1</sup><institution>Goethe University Frankfurt, University Hospital</institution>, Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, <city>Frankfurt</city></aff><aff id="aff1449"><sup>2</sup><institution>Fraunhofer Institute for Translational Medicine and Pharmacology ITMP</institution>, Theodor-Stern-Kai 7, 60596, Frankfurt am Main, <country>Germany</country></aff><aff id="aff1450"><sup>3</sup>Department of Molecular Medicine, <institution>University of Siena School of Medicine</institution>, <city>Siena</city>, <country>Italy</country></aff><aff id="aff1451"><sup>4</sup><institution>Medical Center Anima</institution>, <city>Alken</city>, <country>Belgium</country></aff><aff id="aff1452"><sup>5</sup><institution>CEN (Centro especializado en Neurociencias)</institution>, <city>C&#x000f3;rdoba</city>, <country>Argentina</country></aff><aff id="aff1453"><sup>6</sup><institution>Janssen EMEA</institution>, <city>Sofia</city>, <country>
Bulgaria</country></aff><aff id="aff1454"><sup>7</sup><institution>Janssen Pharmaceutica NV</institution>, <city>Beerse</city>, <country>Belgium</country></aff><aff id="aff1455"><sup>8</sup><institution>Janssen EMEA</institution>, <city>Dublin</city>, <country>Ireland</country></aff><aff id="aff1456"><sup>9</sup>Department of Psychiatry and Psychotherapy, <institution>Semmelweis University</institution>, <city>Budapest</city>, <country>Hungary</country></aff><author-notes><corresp id="cor0487"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="601">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S300</fpage><lpage>S301</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824006266a.pdf"/><abstract><sec id="sec2925"><title>Introduction</title><p>In ESCAPE-TRD, esketamine nasal spray (ESK-NS) significantly increased the probability of remission at Week (Wk)8 and being relapse&#x02011;free through Wk32 after remission at Wk8 versus (vs) quetiapine extended-release (QTP-XR), in patients (pts) with treatment resistant depression (TRD). Safety data were consistent with established profiles of each treatment, with no new safety signals identified (Reif <italic toggle="yes">et al.</italic> DGPPN 2022; P-01-04).</p></sec><sec id="sec2926"><title>Objectives</title><p>To explore weight changes and their impact on treatment discontinuation in ESCAPE-TRD.</p></sec><sec id="sec2927"><title>Methods</title><p>ESCAPE&#x02011;TRD (NCT04338321) was a randomised, open-label, rater-blinded, phase IIIb trial comparing efficacy and safety of ESK-NS vs QTP-XR in pts with TRD. Safety analyses were conducted on pts who received &#x02265;1 dose of study treatment. Treatment-emergent adverse events (TEAEs) were defined as occurring at or after the first dose of study treatment and within 14 days/30 days (non-serious/serious) of the last dose. A &#x02265;7% increase/decrease in weight from screening was considered for evaluation as a TEAE. Weights were measured and are reported as observed, with no missing data imputation.</p></sec><sec id="sec2928"><title>Results</title><p>336 and 340 pts were randomised to ESK-NS and QTP-XR; 334 and 336 were included in the safety population. Over the 32-week study, a TEAE of weight increase was reported in fewer pts treated with ESK-NS than QTP-XR (9 [2.7%] vs 42 [12.5%]), leading to treatment discontinuation in 0 vs 6 (1.8%) pts, respectively. Incidences of weight increase TEAEs were balanced across pts categorised as normal, overweight or obsese by baseline body mass index (BMI; <bold>Figure</bold>). A weight decrease TEAE was reported in 7 pts (2.1%) in the ESK-NS arm vs 0 pts in the QTP-XR arm. Mean (standard deviation [SD]) weight at baseline was 76.4 (16.2) kg (ESK-NS; n=334) vs 79.1 (16.9) kg (QTP-XR; n=336). At Wk32, mean weight was maintained (76.5 [16.3] kg) in ESK-NS treated pts (n=249; mean [SD] change from baseline: 0.1 [4.0] kg) and increased (80.7 [15.6] kg) in QTP-XR treated pts (n=203; mean [SD] change from baseline: 2.5 [5.1] kg).</p><p>
<bold>Image:</bold>
</p><p><fig position="float" id="fig0071"><graphic xlink:href="S0924933824006266-FIG0071" position="anchor"/></fig>
</p></sec><sec id="sec2929"><title>Conclusions</title><p>Increase in weight was uncommon with ESK-NS; weight increases were more common with QTP-XR and resulted in more treatment discontinuations. Weight increase was independent from baseline BMI.</p></sec><sec id="sec2930"><title>Acknowledgements</title><p>We thank the patients who participated. Funding: Janssen, medical writing: Costello Medical, UK</p></sec><sec id="sec2931"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>